Uzel Fatma Işıl, İliaz Sinem, Karataş Ferhan, Çağlayan Benan
Department of Pulmonology, Koç University Hospital, İstanbul, Turkey.
Turk Thorac J. 2020 Nov;21(6):451-453. doi: 10.5152/TurkThoracJ.2020.20123. Epub 2020 Nov 1.
Coronavirus disease 2019 (COVID-19) has become a game changer in many aspects of clinical practice. Acute exacerbations of idiopathic pulmonary fibrosis (IPF) are known as serious events, which can reach a mortality rate of 50%, where viral infections may play a role. We describe the case of a 64-year-old male patient with a diagnosis of IPF under antifibrotic treatment for 1 year; the patient tested positive for COVID-19 with polymerase chain reaction test of the nasopharyngeal swab, and his chest computed tomography results were compatible with COVID-19 pneumonia described in the literature as well as the findings compatible with interstitial lung disease. The patient was successfully treated in the pulmonology ward according to official guidelines about COVID-19 along with antifibrotic treatment and required only a short course of oxygen therapy. We experienced no drug interactions, serious side effects, or complications during treatment. The patient was discharged after 1 week, and he is still in a good condition after 3 weeks. COVID-19 pneumonia in a patient with IPF who survived under antifibrotic treatment without serious deterioration is a new experience. Such cases will probably change our perspective in treating patients with IPF.
2019冠状病毒病（COVID-19）已成为临床实践诸多方面的变革因素。特发性肺纤维化（IPF）急性加重是严重事件，死亡率可达50%，病毒感染可能在其中起作用。我们描述了一例64岁男性患者，诊断为IPF，接受抗纤维化治疗1年；该患者鼻咽拭子聚合酶链反应检测COVID-19呈阳性，其胸部计算机断层扫描结果与文献中描述的COVID-19肺炎相符，也与间质性肺疾病的表现相符。根据关于COVID-19的官方指南，该患者在呼吸内科病房接受了成功治疗，同时进行了抗纤维化治疗，仅需短期吸氧治疗。治疗期间未出现药物相互作用、严重副作用或并发症。患者1周后出院，3周后仍状况良好。在接受抗纤维化治疗且未出现严重病情恶化的情况下存活的IPF患者发生COVID-19肺炎是一种新情况。此类病例可能会改变我们治疗IPF患者的观点。
